We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arthro Kinetics | LSE:AKI | London | Ordinary Share | GB00B0XQ4466 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.10 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 3440Z
Arthro Kinetics plc
18 July 2008
Japanese Submission for CaReS® Clinical Studies
FRIDAY, 18th July 2008 * Arthro Kinetics plc (AIM: AKI) (*Arthro Kinetics* or the *Company*), the orthopedics company dedicated to
regenerating joint mobility and spinal disc function announces that PolarisRx, Arthro Kinetics* joint venture partner has successfully
completed and submitted its Kakunin Shinsei to the Japanese Ministry of Health and Welfare seeking approval to begin clinical studies for
CaRaS® in Japan.
In addition, Arthro Kinetics* joint venture partner in China, Arthro-ANDA Tinajin Biologics Technology Co. (*AATBT*), has received a grant
from the Special Funds for Technology Innovation of Tianjin Municipal Government, for a sum of RMB 8 million (EUR740,000). These monies will
be used by AATBT to advance CaReS® into clinical studies in China in the second half of 2008.
Jason Loveridge, CEO of Arthro Kinetics comments; *These are both important events for AKI signaling the advancement of our autologous
chrondrocyte implant - CaReS® - into clinical studies in important markets for the Company and the continuing success of our joint ventures
in Japan & China.*
CONTACTS
Arthro Kinetics Plc Tel: +49 (0)711 305 110 70
Jason Loveridge, Chief Executive Officer
Doug Quinn, Chief Financial Officer
Nomura Code Securities Limited Tel: +44 (0)207 776 1200
Richard Potts
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGUUGCMUPRGAM
1 Year Arthro Kinetics Chart |
1 Month Arthro Kinetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
